tert-Butyl 3-methyl-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate

Catalog No.: 
ACGNUV536
CAS No.: 
1782614-12-3
Molecular Formula: 
C12H19N3O2
Molecular Weight: 
237.30
tert-Butyl 3-methyl-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$183.00In stockInquiry
250mg97%$307.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 3-methyl-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate
IUPAC Nametert-butyl 3-methyl-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate
Molecular FormulaC12H19N3O2
Molecular Weight237.30
SMILESO=C(N1CC2=CN=C(C)N2CC1)OC(C)(C)C
InChI KeyYKXQFBOJGGYDSO-UHFFFAOYSA-N
SynonymImidazo[1,5-a]pyrazine-7(8H)-carboxylic acid, 5,6-dihydro-3-methyl-, 1,1-dimethylethyl ester;tert-butyl 3-methyl-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxylate;tert-Butyl 3-methyl-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate
CAS No.1782614-12-3

Synthetic Route by SureRoute

1. ACGNUV536 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACOGCL582 route compound structure diagram
    ACOGCL582601515-50-8In Stock
  4. Then
  5. ACGNUV536 route product structure diagram
    ACGNUV5361782614-12-3In Stock
Inquiry

2. ACGNUV536 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGNUV536 route product structure diagram
    ACGNUV5361782614-12-3In Stock
Inquiry

3. ACGNUV536 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGNUV536 route product structure diagram
    ACGNUV5361782614-12-3In Stock
Inquiry

Comments (0)